Poly-(ADP-ribose) Polymerase-1 (Parp-1) Binds in a Sequence-specific Manner at the Bcl-6 Locus and Contributes to the Regulation of Bcl-6 Transcription
Overview
Affiliations
Bcl-6 is a transcription factor that is normally expressed in germinal centre B cells. It is essential for the formation of germinal centres and the production of high-affinity antibodies. Transcriptional downregulation of Bcl-6 occurs on terminal differentiation to plasma cells. Bcl-6 is highly expressed in B-cell non-Hodgkin's lymphoma and, in a subset of cases of diffuse large cell lymphoma, the mechanism of Bcl-6 overexpression involves interruption of normal transcriptional controls. Transcriptional control of Bcl-6 is, therefore, important for normal antibody responses and lymphomagenesis, but little is known of the cis-acting control elements. This report focuses on a region of mouse/human sequence homology in the first intron of Bcl-6, which is a candidate site for such a control element. We demonstrate that poly-(ADP-ribose) polymerase-1 (Parp-1) binds in vitro and in vivo to specific sequences in this region. We further show that PARP inhibitors, and Parp-1 knockdown by siRNA induce Bcl-6 mRNA expression in Bcl-6 expressing cell lines. We speculate that Parp-1 activation plays a role in switching off Bcl-6 transcription and subsequent B-cell exit from the germinal centre.
Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B Front Oncol. 2023; 13:1295579.
PMID: 38111536 PMC: 10726039. DOI: 10.3389/fonc.2023.1295579.
Mechanism and regulation of secondary immunoglobulin diversification.
Bello A, Hirth G, Voigt S, Tepper S, Jungnickel B Cell Cycle. 2023; 22(18):2070-2087.
PMID: 37909747 PMC: 10761156. DOI: 10.1080/15384101.2023.2275397.
Okamoto H, Takasawa S Proc Jpn Acad Ser B Phys Biol Sci. 2021; 97(8):423-461.
PMID: 34629354 PMC: 8553518. DOI: 10.2183/pjab.97.022.
Lee E, Konstantinopoulos P Ther Adv Med Oncol. 2020; 12:1758835920944116.
PMID: 32782491 PMC: 7383615. DOI: 10.1177/1758835920944116.
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies.
Yelamos J, Moreno-Lama L, Jimeno J, Ali S Cancers (Basel). 2020; 12(2).
PMID: 32046278 PMC: 7072203. DOI: 10.3390/cancers12020392.